The RestoreX™ is the subject of a patent validating the exclusivity of the dual traction force technology. It is manufactured in the USA by PathRight Medical, located in Orem, Utah.
The RestoreX™ was invented by Dr. Landon TROST, an American Urologist specializing in Lapeyronie's disease and author of multiple studies and clinical recommendations concerning this pathology. He has no professional or financial ties with PathRight Medical, and his clinical publications concerning Lapeyronie's disease or the RestoreX™ have all been carried out in accordance with the ethical and scientific procedures defined by the AUA (American Urology Association).
The axial traction force is between 2.5 and 3 Kg and that on the counter-curvature between 4.5 and 5 Kg. The power of these tractions is the main reason for the RestoreX™'s effectiveness and has no equivalent among other traction-therapy devices. To ensure that the penis does not escape when traction is applied, the glans is clamped onto a very wide base allowing it to be firmly secured and, to avoid pain, the pressure to be distributed over a large contact area.
The RestoreX™ is effective for correcting penile curvature but also for treating hourglass yards.
The RestoreX™ is the only treatment to have shown tangible results concerning recovery of penile length 1b, 2b.
The RestoreX™ benefits from CE marking, which classifies it as a genuine Medical Device.
Comparison of penile traction devices
Sources: Websites and user manuals of various manufacturers
| RestoreX™ | AndroPenis | X4 | PeniMaster | |
|---|---|---|---|---|
| Duration of treatment | 30 to 60 min/day | 9 hours/day | 5 hours/day | 3 hours/day |
| Invention developed by a doctor specializing in Lapeyonie disease | ||||
| Double traction force | ||||
| Focusing traction on the deformation zone | ||||
| Prospective randomized clinical trials for Lapeyronie's disease | ||||
| Randomized clinical trials for post-prostatectomy lengthening of the penis | ||||
| FDA approval and CE marking | ||||
M.J. Ziegelmann & al. - 2019: Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial
110 patients, mean age 58 years, Lapeyronie anteriority: 49 months, mean curvature 59.3 degrees.
4 groups: 1 control group (number = 27) and 3 other RestoreX ™ groups with daily sessions of use: group 1 (number =28) → 30 min session, group 2 (number =28) → 60 min session, group 3 (number =27) → 90 min session. RestoreX use time divided equally (50/50) into axial traction and counter-curvature.
A. Results at 3 months, average use 47mn/day
- Reduction of curvature by 17.2° or 28%, for 77% of patients who responded to treatment (control group
= +1.3°). Of these 77%, or around 4 out of 5 men, who saw a reduction in curvature, 28% achieved a reduction in curvature of 20°, and for 48% of these 77%, the reduction in curvature was greater than 20°. - Recovery of penis length: +1.6cm or +11% for 94% of patients who responded to treatment
(control group = +0.3cm). - Improved erectile function according to IIEF score of 4.3 (control group = 0.7).
- 47% of patients were unable to have sex with their partner due to insufficient penile tumescence: at the end of 12 weeks of treatment, 80% of these reported being able to penetrate their partner.
- No adverse effects were noted (haematomas, petechiae,...)
- 100% of patients who had already tried another traction-therapy device said they preferred the RestoreX™.
B. 2 additional phases of clinical study at 6 (n=64) and 9 (n=63) months follow-up, daily use
average 31 min/day
- 63% of patients reported improvements in curvature and length (+0.5 cm).
- The International Index of Erectile Function (IIEF) questionnaire score was also increased.
- 84% of patients continued to use RestoreX™ after 9 months.
The mean curvature observed in this study was 59.3°, which virtually classifies this value as severe (> 60°). The mean curvature, reported by clinical studies, is generally between 30° and 50°.
The mean anteriority of Lapeyronie's disease is 49 months implying exponential hardness over time of the fibrosis plaque as well as increasing retraction of the albuginea.
These 2 very demanding criteria represent a real challenge for the RestoreX™.
23% of patients saw no improvement. We tried to understand why these patients weren't responding, and the explanations varied: some weren't using the device properly, others weren't using it at all, and still others were probably doing everything right but getting no response. We do not know why the latter group did not respond.
The reduction in curvature at 3 months is 17.2°, i.e. 28% improvement which represents a considerable evolution. Degrees are an absolute way of measuring angulation, while percentage is a relative value that varies according to the extent of the curvature.
For example, if a person has a curvature of 100° that will be reduced by 40° with the RestoreX™, they will see an improvement of 60° and also 60%. But, if another person whose curvature is 40° registers, as in the clinical study, an improvement of 20°, she will recognize an improvement of 50% compared with the original curvature.
Consultez nos études cliniques ainsi que leurs synthèses pour vérifier l’efficacité du RestoreX™
Étude N°1A | Étude N°2A | Étude N°3A | Étude N°4A | Étude N°5A | Étude N°6A |
M.J. Ziegelmann & al.: Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial / AUA - The Journal of Urology – September 2019, Volume 202, Page: 599-610
Étude clinique prospective et randomisée de la thérapie par traction
pénienne avec le RestoreX™ chez les hommes atteints de la maladie de Lapeyronie : résultats de la phase initiale (3 mois).
J. Joseph & al.: Outcomes of RestoreX™ Penile Traction Therapy in Men with Peyronie’s Disease: Results from Open Label and Follow-up Phases / The Journal of Sexual Medecine – 2020; 17:2462-2471
Étude clinique prospective et randomisée de la thérapie par traction pénienne avec le RestoreX™ chez les hommes atteints de la maladie de Lapeyronie : résultats de la phase de suivi (6 et 9 mois) après la phase initiale (3 mois).
K. Wymer & al.: Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie’s Disease in an Era of Effective Clinical Treatment / The Journal of Sexual Medecine - 2019;16:1421e1432
Comparaison du rapport coût-efficacité aux Etats-Unis de 3 thérapies de la maladie de Lapeyronie : RestoreX (traction-thérapie) vs Collagenase de Clostridium Histolyticum vs Chirurgie.
M.J. Ziegelmann & al.: Clinical Experience with Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie’s Disease / AUA - The Journal of Urology – January 2017104: 108
Évaluation du traitement de la maladie de Lapeyronie avec le Collagénase de Clostridium Histolyticum (CCH) associé à un dispositif de traction-thérapie (Andropenis™).
M. Alom & al.: Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX™ Penile Traction Therapy in Men with Peyronie’s Disease / The Journal of Sexual Medecine - 2019;16:891e900
Évaluation de la sécurité et l'efficacité du RestoreX™ associé à la Collagénase de Clostridium Histolyticum (CCH) par rapport à la CCH seule et à la CCH associée à d'autres dispositifs de traction-thérapie (AndroPenis™, X4 Labs Penis Extender™ et PeniMaster™).
B. Green & al.: Comparison of Collagenase Clostridium histolyticum to Surgery for the Management of Peyronie’s Disease: A Randomized Trial / The Journal of Urology 210(5):p 791-802, November 2023.
Étude clinique prospective et randomisée comparant la thérapie de la maladie de Lapeyronie entre 1 groupe Collagénase de Clostridium Histolyticum + RestoreX™ + Sildenafil (groupe CCH) versus une autre thérapie Chirurgie + RestoreX™ + Sildenafil (groupe chirurgie).
The RestoreX™ is marketed by Med'Arte a French company specialized in selling medical devices for Urology to healthcare institutions.
-
2 extension rods only
48,00€
-
Pelvic ring
36,00€
-
Lower clamp
48,00€
-
Upper clamp
60,00€
-
SHIPPING COST
50,00€
